RESORCE

NCT01774344 📎

Regimen

Experimental
regorafenib 160 mg/day weeks 1-3 of each 4-week cycle + BSC
Control
placebo + BSC

Population

Hepatocellular carcinoma who tolerated sorafenib and progressed on it, Child-Pugh A

Key finding

mOS 10.6 vs 7.8 mo (HR 0.63, 95% CI 0.50-0.79, p<0.0001); **first positive post-sorafenib 2L phase 3 in HCC**; ITT included only sorafenib-tolerant patients (strict selection); etiology HBV 38%, HCV 21%, alcohol 24%

Source: PMID 27932229

Timeline

    Guideline citations

    • NCCN HCC (p.18)